Abstract 347P
Background
Controversy exists regarding the optimal margin of surgical excision for cutaneous squamous cell carcinoma (cSCC). Japanese clinical practice guidelines for skin cancer (second edition) recommend an excision with a 4–6-mm clinical margin for low-risk cSCC and >6-mm clinical margin for high-risk cSCC. However, it is difficult to follow this guideline for all cSCCs because high-risk cSCCs frequently occur on the face or in older patients. The purpose of this study was to investigate the correlation between surgical margin and prognosis in patients with cSCC.
Methods
Patients with cSCC who underwent surgical excision of the primary site between 2011 and 2019 at Saitama Medical University International Medical Center were included in this retrospective observational study. Patients were divided into two groups: group A (standard surgery with guideline-recommended margin) and group B (modified surgery with narrow margin). Overall survival (OS), relapse-free survival (RFS), local recurrence-free survival (LRFS), regional metastasis-free survival (RMFS), and distant metastasis-free survival (DMFS) were compared between the two groups.
Results
A total of 107 patients with cSCC were included in this study: 39 in group A and 68 in group B. There were no significant differences in patient characteristics such as sex, tumor border, and risk factors; age and tumor size differed between groups. There were no statistically significant differences in OS (p=.470), LRFS (p=.631), RMFS (p=.502), and DMFS (p=.475) between the two groups. However, RFS was significantly lower in group A than in group B (p=.049).
Conclusions
This study did not reveal a significant impact of clinical margin on OS in patients with cSCC. Although this conclusion may have been limited by selection bias, excision with narrower margins than those suggested by current guidelines may be appropriate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract